Transcriptional regulation of genes encoding drug and bile acid transporters: implications for liver and intestinal diseases by Eloranta, J J
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
Transcriptional regulation of genes encoding drug and bile acid
transporters: implications for liver and intestinal diseases
Eloranta, J J
Eloranta, J J. Transcriptional regulation of genes encoding drug and bile acid transporters: implications for liver and
intestinal diseases. 2009, University of Zurich, Faculty of Medicine.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
University of Zurich, Faculty of Medicine, 2009.
Eloranta, J J. Transcriptional regulation of genes encoding drug and bile acid transporters: implications for liver and
intestinal diseases. 2009, University of Zurich, Faculty of Medicine.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
University of Zurich, Faculty of Medicine, 2009.
 HABILITATIONSSCHRIFT  
 
 
Transcriptional regulation of genes encoding 
drug and bile acid transporters: 
implications for liver and intestinal diseases 
 
 
 
zur Erreichung der Venia Legendi  
der Universität Zürich  
 
 
vorgelegt von  
Dr. Jyrki Johannes Eloranta, Ph.D. 
 
Zürich, 4. May 2008  
 
 
 
 
 
 
Klinik für Klinische Pharmakologie und Toxikologie  
Departement für Innere Medizin  
Universitätsspital Zürich  
Direktor: Prof. Dr. med. Gerd A. Kullak-Ublick  
 
Jyrki J. Eloranta                                       Habilitationsschrift: Regulation of enterohepatic transporter genes in health and disease 
 
Table of contents 
 
1. Publications 
1.1. Five original publications discussed in the cumulative "Habilitationsschrift".........................1 
1.2. Three original publications of high scientific value, not discussed in the cumulative 
       "Habilitationsschrift"..............................................................................................................1 
 
2. Background to the presented work....................................................................................................2 
2.1. Membrane transporters in the liver and the intestine............................................................2 
2.2. Members of the SLC22A family of transporters in the liver.................................................. 2 
2.3. Enterohepatic bile acid transport...........................................................................................3 
 
3. Synopsis of the selected publications................................................................................................3 
 
4.  Detailed discussion of the selected publications...............................................................................4 
4.1. The hOCT1 gene is transactivated by HNF-4α (Paper 1).......................................................4 
4.2. The hOAT2 gene is transactivated by HNF-4α and suppressed by bile acids (Paper 2)........5 
4.3. The hNTCP gene is activated by GR and PGC-1α, and suppressed by bile acids via a 
       SHP-dependent mechanism (Paper 3)....................................................................................6 
4.4. The nuclear receptor for bile acids, FXR, transactivates the human OSTα and OSTβ 
       genes (Paper 4).......................................................................................................................7 
4.5. Regional distribution of SLC mRNA expression along the human intestinal tract (Paper 5)...8 
 
5. Value of the presented work...............................................................................................................9 
 
  
Jyrki J. Eloranta                                       Habilitationsschrift: Regulation of enterohepatic transporter genes in health and disease 
 1
1. Publications 
 
1.1. Five original publications discussed in the cumulative "Habilitationsschrift" 
 
* denotes equal contribution ; # denotes corresponding author ; IF= impact factor, 2006 JCR 
Science Edition 
 
Paper 1:  
Saborowski, M., Kullak-Ublick, G.A., and #Eloranta, J.J. (2006) The human organic cation 
transporter 1 gene is transactivated by hepatocyte nuclear factor-4α. Journal of Pharmacology and 
Experimental Therapeutics, 317, 778-785. (IF: 3.956)  
 
Paper 2: 
*Popowski, K., *Eloranta, J.J., Saborowski, M., Fried, M., Meier, P.J., and Kullak-Ublick, G.A. 
(2005) The human organic anion transporter 2 gene is transactivated by hepatocyte nuclear factor-
4α and suppressed by bile acids. Molecular Pharmacology, 67, 1629-1638. (IF: 4.469) 
 
Paper 3: 
Eloranta, J.J., Jung, D., and Kullak-Ublick, G.A. (2006) The human Na+-taurocholate cotransporting 
polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated 
receptor-γ coactivator 1α, and suppressed by bile acids via a small heterodimer partner-dependent 
mechanism. Molecular Endocrinology, 20, 65-79. (IF: 4.967) 
 
Paper 4: 
*Landrier, J.-F., *Eloranta, J.J., Vavricka, S.R., and Kullak-Ublick, G.A. (2006) The nuclear receptor 
for bile acids, FXR, transactivates the human organic solute transporter-α and -β genes. American 
Journal of Physiology - Gastrointestinal and Liver Physiology, 290, G476-G485. (IF: 3.681) 
 
Paper 5: 
Meier, Y., #Eloranta, J.J., Darimont J., Ismair, M.G., Hiller, C., Fried, M., Kullak-Ublick, G.A., and 
Vavricka, S.R. (2007) Regional distribution of solute carrier mRNA expression along the human 
intestinal tract. Drug Metabolism and Disposition, 35, 590-594. (IF: 3.638) 
 
 
 
1.2. Three original publications of high scientific value, not discussed in the cumulative 
"Habilitationsschrift" 
 
Eloranta, J.J., and Hurst, H.C. (2002) Transcription factor AP-2 interacts with the SUMO-
conjugating enzyme UBC9 and is sumolated in vivo. Journal of Biological Chemistry, 277, 30798-
30804. (IF: 5.808) 
 
*Bamforth, S.D., *Bragança, J., Eloranta, J.J., Murdoch, J.N., Marques, F.I.R., Kranc, K.R., Farza, 
H., Henderson, D.J., Hurst, H.C., and Bhattacharya, S. (2001) Cardiac malformations, adrenal 
agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co-activator. 
Nature Genetics, 29, 469-474. (IF: 24.176) 
 
Eloranta, J.J., Kato, A., Teng, M.S., and Weinzierl, R.O.J. (1998) In vitro assembly of an archaeal 
D-L-N RNA polymerase subunit complex reveals a eukaryote-like structural arrangement. Nucleic 
Acids Research, 26, 5562-5567. (IF: 6.317) 
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2. Background to the presented work 
 
2.1. Membrane transporters in the liver and the intestine 
Polarized intestinal epithelium selectively translocates compounds from the intestinal lumen to the 
blood circulation. Intestinal absorption of drugs, bile acids, nutrients, and other molecules is mediated 
by uptake transporter proteins expressed at the apical enterocyte membranes. These compounds may 
be returned to the intestinal lumen or released into the blood circulation by intestinal efflux transporters 
expressed at apical or basolateral membranes, respectively. From portal blood these substances are 
taken up into the liver, the chief organ for drug metabolism and elimination, by transporters at the 
basolateral membranes of hepatocytes. Following their metabolism by phase I and phase II enzymes, 
the compounds may be released into bile for subsequent fecal elimination by the action of transporters 
at the canalicular membranes of hepatocytes, or returned back into blood circulation by basolateral 
efflux transporters. 
           Expression levels of intestinal and hepatic transporters importantly contribute to the degree of 
absorption and distribution of their substrates, and are thus crucial determinants of pharmacokinetics 
of many drugs. Expression levels of transporters are frequently altered in diseases of the intestine and 
liver, such as inflammatory bowel disease and cholestatic disease, respectively. Changes in 
transporter expression may contribute to the pathological process, or, as a consequence of the 
pathologies, may lead to aberrant drug absorption and elimination in the affected patients.  
 
2.2. Members of the SLC22A family of transporters in the liver 
The transport and metabolism of organic cationic and anionic drugs and endobiotics are essential 
tasks performed by hepatocytes. The SLC22A family of poly-specific organic cation and anion 
transport proteins (OCTs and OATs, respectively) are crucial mediators of the uptake of a range of 
drugs and endobiotics into liver parenchymal cells from portal blood. Three members of the SLC22A 
family are abundantly expressed in the human liver, and are localized to the basolateral membranes of 
hepatocytes: hOCT1 (SLC22A1), hOAT2 (SLC22A7), and the very recently characterized hOAT7 
(SLC22A9). 
          The hOCT1 protein mediates hepatic uptake of cationic drugs and endogenous substrates, such 
as dopamine, serotonin, metformin, cimetidine, verapamil, ganciclovir, and choline, from portal blood. 
A net positive charge is not absolutely required for hOCT1 substrates, as it has been shown to also 
transport certain anionic prostaglandins. Studies with Oct1-null mice support the notion that Oct1 is the 
major physiological hepatic uptake system for small organic cations. The SLC22A1 gene is located on 
chromosome 6, contains seven exons and six introns, and can produce several alternatively spliced 
mRNA isoforms. 
          The OAT transporters differ structurally from the members of the OATP (organic anion 
transporting polypeptide) family: While the OATPs typically transport larger and more lipophilic organic 
anions, the OATs are efficient transporters of small hydrophilic organic anions. The hOAT2 protein 
mediates sodium-independent uptake of compounds, such as p-aminohippurate, cephalosporins, 
salicylates, tetracyclines, dicarboxylates, prostaglandins, and methotrexate, from portal blood into the 
parenchymal cells of the liver. The SLC22A7 gene is located on chromosome 6 and contains ten 
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exons and nine introns. An alternatively spliced transcript lacking the second exon has been 
described. 
 
2.3. Enterohepatic bile acid transport 
Bile acids are physiological detergents that play essential roles in promoting absorption, excretion, and 
transport of cholesterol, lipids, and lipophilic nutrients in the liver and the intestine. They are 
synthesized from cholesterol in the liver and stored in the gallbladder, from which they are post-
prandially released into the small intestine. From the small intestine the bile acids are recycled back to 
the liver via portal blood. A bile acid molecule may shuttle up to a dozen times between the liver and 
the intestine during one day, each time crossing the membrane domains of hepatocytes and 
enterocytes. This enterohepatic cycling of bile acids is highly efficient in healthy humans: less than 
10% of the bile acid pool escapes ileal reabsorption and enters the colon. In the colon, secondary bile 
acids are formed, which may be either passively absorbed into colonocytes, or lost through fecal 
excretion. The small loss into feces is compensated for by hepatic de novo synthesis of bile acids, 
catalyzed by cascades of cytochrome P450 enzymes. Thus, conversion of cholesterol into bile acids is 
an important route for elimination of cholesterol from the body. Disruption of the biliary secretion of bile 
acids may result in cholestasis, where intrahepatic and systemic accumulation of bile acids causes 
cytotoxicity. This may eventually progress to liver fibrosis and cirrhosis. 
          Enterohepatic circulation of bile acids is mediated by integral plasma membrane transporters, 
expressed in hepatocytes and enterocytes in a polarized manner. Following their synthesis, bile acids 
are excreted from hepatocytes into bile canaliculi by the bile salt export pump (BSEP), which belongs 
to the superfamily of ATP-binding cassette transporters. After their passage to the intestinal lumen, 
bile acids are efficiently taken up into ileocytes via the apical sodium-dependent bile acid transporter 
(ASBT). At the basolateral membrane domain of ileal enterocytes, bile acids are extruded into portal 
blood by the heterodimeric organic solute transporter OSTα/OSTβ. To complete their enterohepatic 
circulation, bile acids are extracted from the portal blood circulation into the liver by the Na+-
taurocholate cotransporting polypeptide (NTCP) at the sinusoidal membrane of hepatocytes. 
          The role for bile acids as physiological detergents has long been recognized. Recently, bile 
acids have been identified as ligands for specific members of the nuclear receptor family of 
transcription factors, particularly the farnesoid X receptor (FXR). Because of this signalling function of 
bile acids, changes in intracellular levels of bile acids have a profound feedback effect on the 
transcriptional regulatory circuits involved in bile acid transport and metabolism. The transcriptional 
responses to elevated bile acid levels decrease synthesis and cellular uptake of bile acids, and 
increase their efflux and detoxification systems. This response protects the hepatocytes or enterocytes 
from damaging detergent effects of excessive levels of intracellular bile acids. 
 
3. Synopsis of the selected publications 
In the work discussed in this Habilitationsschrift, detailed molecular mechanisms, by which the 
expression levels of both hepatic and intestinal transporter genes are regulated have been studied, 
Specifically, it was shown that the liver-enriched member of the nuclear receptor transcription factor 
family, hepatocyte nuclear factor-4α (HNF-4α), as well as intracellular bile acids adjust the 
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transcription of the two genes encoding hepatic uptake transporters hOCT1 and hOAT2, which extract 
a wide range of drugs from portal blood into hepatocytes. Furthermore, the pathways that adjust the 
expression levels of hepatic (NTCP) and intestinal (OSTα/OSTβ and ASBT) bile acid transporter 
genes have been investigated, leading to better understanding of the pathophysiology of disturbances 
in enterohepatic cycling of bile acids. Finally, a comprehensive investigation into the regional 
distribution in expression levels of members of the solute carrier (SLC) transporter family in the human 
intestine was executed.  
 
4. Detailed discussion of the selected publications 
 
4.1. The hOCT1 gene is transactivated by HNF-4α (Paper 1) 
Changes in the expression level of the hOCT1 transporter are likely to influence the uptake rate of 
hepatic clearance of hOCT1 substrates from sinusoidal blood. While the signalling pathways that 
regulate the functional activity of the hOCT1 protein had been previously studied, little was known 
about the regulation of the hOCT1 gene. In this study we first perfomed an in silico analysis of the 5’-
flanking promoter region of the hOCT1 gene and identified two adjacent putative binding sites for the 
transcription factor hepatocyte nuclear factor HNF-4α between nucleotides -1479 to -1441 upstream of 
the transcription initiation site. HNF-4α is a liver-enriched nuclear receptor that plays a crucial role in 
hepatocyte differentiation and maintenance of the hepatic gene expression profile. Its target genes 
encode proteins involved in a range of physiological processes, notably cholesterol, bile acid, and 
glucose metabolism. HNF-4α binds as a homodimer to its preferred DNA response elements within 
the target promoters. 
            Each putative response element for HNF-4α within the hOCT1 promoter was found to be of the 
DR-2 format, containing directly repeated hexamers (AGGTCA-like), separated by two bases. In 
electrophoretic mobility shift assays both elements directly interacted with HNF-4α. The sequences of 
the two DR-2 motifs are entirely conserved between the human and chimpanzee OCT1 promoters, 
supporting the functional importance of these elements in regulation of the OCT1 genes in primates. 
However, no such conservation was readily apparent in the promoter regions of the rat and mouse 
Oct1 genes. A luciferase reporter construct containing the hOCT1 promoter was strongly activated by 
HNF-4α in transiently transfected liver-derived Huh7 cells. Site-directed mutagenesis of either DR-2 
element alone, or in combination, severely decreased the HNF-4α-mediated activation of the hOCT1 
promoter, indicating that the integrity of both elements is functionally important. Unlike most nuclear 
receptors, the activity of HNF-4α may not be readily modulated by exogenously administered ligands, 
as the crystal structure of its ligand-binding domain suggests that it is constitutively bound by 
endogenous fatty acids. However, HNF-4α responds to extra- and intracellular signals through 
pathways that modulate its phosphorylation status, providing potential means of altering the 
expression levels of its target genes, including hOCT1. 
          In this study, we also discovered that HNF-4α-supported expression of hOCT1 was efficiently 
suppressed by the bile acid CDCA, consistent with the previous reports that the expression of the rat 
Oct1 is reduced in obstructive cholestasis  and that Oct1 mRNA expression is reduced in mice fed with 
Jyrki J. Eloranta                                       Habilitationsschrift: Regulation of enterohepatic transporter genes in health and disease 
 5
a cholic acid-rich diet. However, as mentioned above, there is no evidence that HNF-4α regulates the 
rodent Oct1 genes, and the exact mechanisms, by which bile acids exert their negative effects on 
OCT1/Oct1 expression, are not necessarily conserved between the species. In the study described 
here, we showed that the synthetic FXR ligand GW4064 and CDCA are equally effective in reversing 
the HNF-4α activation of endogenous hOCT1 mRNA expression in cultured liver cells, indicating that 
this effect depends on the bile acid receptor FXR. Furthermore, overexpression of the FXR-inducible 
repressor SHP counteracted HNF-4α-mediated activation of both the endogenous and reporter-linked 
hOCT1 promoters.  
 
4.2. The hOAT2 gene is transactivated by HNF-4α and suppressed by bile acids (Paper 2) 
The study described here contains many parallels to our investigation into the regulation of the hOCT1 
gene discussed above. Similarly to hOCT1, the mechanisms that control the expression of the hOAT2 
gene were poorly understood prior to this study, even if such regulation may critically influence the rate 
of hepatic clearance of hOAT2 substrates from sinusoidal blood. In the case of the hOAT2 promoter, 
our computer analyses suggested a near-consensus binding site for HNF-4α between nucleotides -
329 to -317 upstream of the transcription initiation site, which HNF-4α could indeed specifically bind to 
in electrophoretic mobility shift assays. A luciferase-linked hOAT2 promoter fragment containing the 
HNF-4α binding site was transactivated upon cotransfection of an HNF-4α expression vector in 
hepatic Huh7 cells, whereas site-directed mutagenesis of this element abolished activation by HNF-
4α. Short interfering RNAs, which efficiently suppressed endogenous HNF-4α expression, also 
markedly reduced endogenous expression of hOAT2 in Huh7 cells, demonstrating the importance of 
HNF-4α in maintaining the baseline level of hOAT2 gene expression in liver-derived cells.  
          Even if the genes coding for the two members of the SLC22A transporter family, hOCT1 and 
hOAT2, are both regulated by HNF-4α, the exact mode of regulation is not identical: whereas there is 
a single direct repeat-1 (DR-1) element with strong binding properties for HNF-4α in the hOAT2 
promoter, the activation of the hOCT1 promoter by HNF-4α depends on two adjacent lower affinity 
DR-2 elements. Furthermore, while the HNF-4α response elements of the hOCT1 promoter are not 
conserved in rodent Oct1 orthologs, highly similar DR-1 element can be identified in a corresponding 
location of both the human and rat OAT2/Oat2 promoters. Given that the overall similarity between the 
human and rat OAT2/Oat2 promoters is low, the conserved HNF-4α-binding element is likely to serve 
a physiologically important role in the regulation of this major drug and xenobiotic transporter in 
mammalian hepatocytes.  
          In an analogous manner to hOCT1, both treatment of hepatic cells with either the bile acid 
CDCA or synthetic FXR agonist GW4064 and exogenous expression of bile acid-inducible repressor 
SHP reversed the HNF-4α effect on both the hOAT2 promoter activity and endogenous hOAT2 mRNA 
expression. Bile acid-mediated suppression of hOAT2 and hOCT1 gene expression could serve to 
coordinately decrease the hepatocellular uptake of drugs and xenobiotics by these two transporters, in 
disease conditions associated with increased intrahepatic concentrations of potentially toxic bile acids, 
such as in cholestasis. 
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          In this study we also observed that, in addition to negatively affecting the transactivation 
potential of HNF-4α bound to the DR-1 element on the hOAT2 promoter, bile acids and GW4064 also 
decreased HNF-4α mRNA and protein levels in liver-derived cells, and consequently reduce nuclear 
HNF-4α binding to DNA. It is possible that FXR-induced SHP is responsible for the suppression of the 
HNF-4α gene, although the critical transcription factor and its binding element within the HNF-4α 
promoter are still under investigation. Apart from acting via a SHP-dependent mechanism, FXR may 
directly bind to a negative response element located in the HNF-4α promoter, a mechanism shown to 
be operative in the context of two human apolipoprotein genes.  
 
4.3. The human NTCP gene is activated by GR and PGC-1α, and suppressed by bile acids via a 
SHP-dependent mechanism (Paper 3) 
The efficiency of bile acid uptake into human hepatocytes is likely to be largely determined by the 
expression level of the hNTCP gene. While several promoter elements and DNA-binding factors had 
previously been suggested to regulate the rat Ntcp gene, transcriptional regulation of the human NTCP 
gene had remained less characterized. This study shows that the hNTCP gene, encoding the chief 
uptake system for bile acids from portal circulation into human hepatocytes, is a novel transcriptional 
target for induction by glucocorticoids via their affinity to the glucocorticoid receptor (GR). Both the 
endogenous hNTCP mRNA expression in hepatoma cells and the reporter-linked hNTCP promoter in 
transiently transfected cells were inducible by GR and its agonistic ligand dexamethasone. While the rat 
Ntcp gene had been previously shown to be subject to multihormonal regulation, our study was the first 
to demonstrate the effects of steroid hormones on human NTCP gene expression. The 
antiglucocorticoid mifepristone (RU486) suppressed GR-activation of hNTCP gene expression, 
demonstrating the specificity of the effect. Mutational analysis of the hNTCP promoter identified a 
functional GR response element immediately upstream of the transcription start site of the hNTCP 
gene. GR directly interacts with this element within living cells, as shown in antibody-facilitated DNA 
precipitation assays. Previous to this study, our group had demonstrated that the hASBT gene is also 
activated by GR in a ligand-dependent manner. It thus appears that glucocorticoids, in a coordinated 
fashion, regulate the expression of the two major bile acid uptake systems in the liver and intestine, 
thereby controlling the efficiency of the enterohepatic circulation of bile acids.  
         We further studied the cofactor requirements for GR-mediated transactivation of the hNTCP gene, 
and discovered that it is coactivated by PGC-1α (peroxisome proliferator-activated receptor-γ 
coactivator-1α). Recently, it has been reported that PGC-1α is also a potent coactivator of the nuclear 
bile acid receptor FXR. Our finding that PGC-1α regulates a crucial bile acid transporter further 
supports a pivotal role for this transcriptional coactivator in the control of bile acid metabolism. 
Interestingly, activation of the hASBT gene by GR was not enhanced by PGC-1α, indicating that PGC-
1α coactivates GR in a promoter-specific manner.   
          Expression of the hNTCP gene is reduced in response to increased intracellular bile acid 
concentrations in cholestatic liver disease. While the molecular mechanism for the bile acid-mediated 
suppression of the hNTCP gene remained unelucidated, the nuclear receptor heterodimer RARα-
RXRα had been identified as the target for downregulation of the rat Ntcp promoter. However, the 
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hNTCP gene is not regulated by RARα-RXRα, so a different molecular mechanism must be 
operational in humans. In this study we found that the GR-activation of endogenous hNTCP 
expression was suppressed by bile acids. This phenomenon depended on the bile acid receptor FXR, 
as efficient suppression of GR-mediated induction of the hNTCP gene was achieved by treatment of 
cells with the specific FXR ligand GW4064. We further showed that exogenous expression of the FXR-
induced transcriptional repressor SHP strongly antagonized GR-dependent induction of hNTCP 
promoter activity and endogenous hNTCP mRNA expression. Evidence was obtained that SHP 
suppressed  PGC-1α-coactivation of the hNTCP promoter via competition between PGC-1α and SHP 
over the same interaction surface in GR. In summary, we elucidated a novel mechanism that mediates 
the bile acid-dependent negative feedback of hepatic bile acid uptake specifically in humans. Similarly 
to hNTCP, the GR-dependent induction of the hASBT gene could be suppressed by SHP, implying 
that GR is also a target for bile acid-mediated suppression of the hASBT gene. 
 
4.4. The nuclear receptor for bile acids, FXR, transactivates the human OSTα and OSTβ genes 
(Paper 4) 
At the basolateral domain of ileal enterocytes, bile acids are extruded into portal blood by the 
heterodimeric organic solute transporter OSTα/OSTβ. The transport function, tissue distribution, and 
subcellular localization of OSTα/OSTβ had been previously well characterized. In view of its function as 
a bile acid export system at the basolateral membrane of enterocytes, we hypothesized that bile acids 
may transcriptionally regulate the expression of the OSTα/OSTβ genes, as previously shown for other 
bile acid transporters, most notably for the liver canalicular bile acid efflux system BSEP. Indeed, we 
obtained strong evidence in this study that human OSTα/OSTβ gene expression is induced by bile acids 
through ligand-dependent transactivation of both OST genes by the nuclear bile acid receptor FXR. The 
FXR agonists induced endogenous mRNA levels of OSTα and OSTβ in cultured established cell lines, 
an effect that was not discernible upon inhibiting FXR expression by small interfering RNAs. 
Furthermore, the OST mRNAs were induced upon exposure to the bile acid CDCA in human ileal 
biopsies from five donors. This novel method of short-term culturing of human ileal biopsies was 
designed in the context of this study, and serves as a unique ex vivo model to study human intestinal 
gene expression patterns in response to nuclear receptors or cytokines. 
          Luciferase reporter constructs containing the OSTα or OSTβ promoters were transactivated by 
FXR in the presence of its ligand. Two functional FXR-binding motifs of the typical inverted repeat-1 
(IR-1) configuration were identified in the OSTα gene, and one in the OSTβ gene. FXR binds binds to 
IR-1 elements as a dimer with the retinoid X receptor (RXRα), a nuclear receptor known to 
productively heterodimerize with a range of other members of the nuclear receptor family. We verified 
that all three IR-1 motifs in OST promoters specifically bound the FXR-RXRα heterodimer in 
electrophoretic mobility shift assays. Targeted mutation of any of these IR-1 elements led to reduced 
inducibility of both OST promoters by FXR. In conclusion, the genes encoding the human OSTα/OSTβ 
complex are induced by bile acids and FXR. It is intriguing that while the human OST genes do not 
exhibit overall sequence similarity and are located on separate chromosomes (the OSTα gene on 
chromosome 3 and the OSTβ gene on chromosome 15), they are both similarly induced through direct 
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binding of FXR to the 5’ regulatory sequences. By coordinated control of OSTα/OSTβ expression, bile 
acids may adjust the rate of their own efflux from enterocytes in response to changes in intracellular 
bile acid levels. Our data complete the loop of FXR-regulated bile acid transporter genes within the 
enterohepatic circulation, and further emphasize the role of FXR as a master regulator of bile acid 
transport at all plasma membrane domains in enterocytes and hepatocytes.  
 
4.5. Regional distribution of solute carrier mRNA expression along the human intestinal tract 
(Paper 5) 
One important transporter superfamily, many members of which are intestinally expressed, is the 
solute carriers (SLCs). SLC expression levels are a critical determinant of the degree of intestinal drug 
absorption, thus affecting distribution and pharmacokinetic characteristics of many drugs. In this study 
we characterized the distribution of 15 human SLC transporter mRNAs in histologically normal 
biopsies from five intestinal regions (duodenum, ileum, colon ascendens, colon transversum, colon 
descendens) of 10 patients. The measurements were performed using TaqMan real-time PCR system 
combined with absolute quantification of SLC cDNA copy numbers vs. villin (intestinal house-keeping 
gene) copy numbers. 
          Out of the 15 SLC genes examined, nine were detectably expressed in at least one intestinal 
region: ASBT, CNT1, CNT2, ENT2, OATP2B1, OCTN1, OCTN2, PEPT1, and SERT. The bile acid 
uptake system ASBT has not been shown to transport drugs, but is an attractive target for delivery of 
prodrugs designed as bile acid derivatives. CNT1, CNT2, and ENT2 are nucleoside transporters 
essential for de novo nucleic acid synthesis, and for anticancer and antiviral therapy with nucleoside 
analogue drugs. OATP2B1 belongs to the family of organic anion transporting polypeptides (OATPs), 
and serves as an uptake system for sulfated sex steroids, benzylpenicillin, pravastatin, and 
fexofenadine. OCTN1 and OCTN2 are organic cation/carnitine transporters, which have attracted 
much attention, as polymorphisms in the genes encoding them have been linked to inflammatory 
bowel disease. The oligopeptide transporter PEPT1 at the apical membrane of intestinal epithelium 
mediates the uptake of nutrient-derived peptides, as well as of peptidomimetic drugs, such as β-lactam 
antibiotics. Colonic expression of PEPT1 is induced in patients suffering from IBD. Serotonin 
transporter (SERT) is a terminator of 5-hydroxytryptamine signalling, by mediating its reuptake at 
basolateral enterocyte membranes. Reduced SERT expression is associated with ulcerative colitis 
and irritable bowel syndrome. 
          Amongst SLCs, we observed three different expression patterns: 1) SLCs predominantly or 
exclusively expressed in the duodenum and ileum (CNT1, CNT2, ASBT, SERT, PEPT1), 2) SLCs 
expressed in all five intestinal sections at similar levels (OCTN1, OATP2B1), 3) SLCs expressed at a 
higher level in colon than in the small intestine (OCTN2, ENT2). None of the SLC mRNAs exhibited 
significantly different expression levels between the three colon segments. We also observed a high 
degree of interindividual variability in SLC expression. This may result from differences in intestinal 
metabolic environment between patients, caused by genetic, hormonal, and dietary variations, or from 
differential exposure to drugs and environmental toxins: These factors may affect transcription of 
specific SLC genes, thus causing transient or long-term changes in mRNA levels. Transcriptional 
regulatory mechanisms have been studied for a few of the SLC genes investigated in this study. Our 
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approach may provide physiological support for such molecular studies, or suggest novel pathways, 
by which the SLC genes are regulated. For example, consistent with the proposal that the human 
ASBT promoter is activated by the glucocorticoid receptor, ileal ASBT mRNA expression was elevated 
in a patient receiving glucocorticoid therapy. OATP2B1 expression was similarly elevated in the ileum 
and colon of the same patient, suggesting that the OATP2B1 gene may also be activated by 
glucocorticoids.  
          Results obtained in healthy subjects form a basis for understanding changes in SLC gene 
expression in intestinal diseases, and may help in adapting therapeutic interventions in such 
pathologies. Determining regional expression levels of drug and prodrug transporters provides 
indications about the site of intestinal absorption of a drug. This may help in designing enterally 
delivered drugs with more accurate absorption properties and more predictable pharmacokinetic 
characteristics. 
 
5. Value of the presented work 
In addition to the inherent basic scientific value in the mechanistic gene regulation studies, 
characterization of the transcriptional mechanisms that mediate alterations in transporter gene 
expression in response to changes in the cellular metabolic environment has yielded important insights 
into factors that affect the efficiency of transmembrane transport in the human liver and intestine. 
Increasing knowledge of the exact mechanisms that regulate hepatic and intestinal drug transporter 
genes may provide us with new tools to modulate drug absorption, elimination, and pharmacokinetics in 
a controlled manner. In the case of bile acid transporters, this work may advance our understanding of 
the pathogenesis of cholestatic diseases, and has provided novel potential targets for therapeutic 
intervention. Quantitative knowledge of transporter expression levels in different regions of the human 
gastrointestinal tract could assist in designing delivery strategies for orally administered drugs and in 
defining any changes in transporter expression that occur in pathological states more precisely, by 
comparison with the expression levels in healthy individuals.  
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Background to the presented work 
 
Membrane transporters in the liver and the intestine. Intestinal absorption of drugs, bile acids, and 
other molecules is mediated by uptake transporters at the apical enterocyte membrane. These 
compounds are returned to the intestinal lumen or released to blood by intestinal efflux transporters at 
apical or basolateral membranes, respectively. From portal blood these substances are taken to the 
liver by transporters at the basolateral hepatocyte membrane. Following their metabolism, the 
compounds may be released into bile for fecal elimination by canalicular transporters or returned to 
blood via basolateral efflux. Transporter expression levels affect the absorption and distribution of their 
substrates. Changes in transporter expression may contribute to pathologies or may lead to aberrant 
drug absorption and elimination in affected patients. 
 
Members of the SLC22A family of transporters in the liver. Organic cation and anion transporters 
(OCTs and OATs) mediate the uptake of drugs and endobiotics into liver cells from portal blood. The 
hOCT1 protein mediates hepatic uptake of substrates, such as dopamine, serotonin, metformin, 
cimetidine, verapamil, and ganciclovir from portal blood. The hOAT2 protein mediates uptake of 
compounds, such as cephalosporins, salicylates, tetracyclines, prostaglandins, and methotrexate from 
portal blood into hepatocytes.  
 
Enterohepatic bile acid transport. Bile acids aid absorption and excretion of lipophilic compounds in 
the liver and the intestine. They are formed in the liver and stored in the gallbladder, from which they 
are released to the intestine. From the intestine bile acids are recycled to the liver via portal blood. 
Enterohepatic cycling of bile acids is efficient in healthy humans: <10% of bile acids escape ileal 
reabsorption. Disruption of biliary bile acid secretion causes cholestasis, where bile acid accumulation 
leads to cytotoxicity. Enterohepatic cycling of bile acids is mediated by membrane transporters: Bile 
acids are excreted from hepatocytes into bile canaliculi by the bile salt export pump (BSEP). After their 
passage to the intestine, bile acids are taken into ileocytes via the apical sodium-dependent bile acid 
transporter (ASBT). At the basolateral ileocyte membrane, bile acids are extruded into portal blood by 
the organic solute transporters OSTα/OSTβ. Bile acids are then returned to the liver by the Na-
taurocholate cotransporting polypeptide (NTCP) at the sinusoidal hepatocyte membrane. Bile acids 
can act as ligands for the farnesoid X receptor (FXR), a nuclear receptor transcription factor. Via this 
signalling ability, elevated bile acid levels decrease bile acid synthesis and uptake, and increase their 
efflux and detoxification. This protects hepatocytes and enterocytes against toxicity by bile acids. 
 
Detailed discussion of the selected publications 
 
The hOCT1 gene is transactivated by HNF-4α (Paper 1). By in silico analysis of the hOCT1 promoter, 
we identified two adjacent binding sites for the transcription factor hepatocyte nuclear factor HNF-4α. 
HNF-4α is a liver-enriched nuclear receptor that plays a crucial role in the maintenance of the hepatic 
gene expression profile. Each putative response element for HNF-4α in the hOCT1 promoter was of the 
DR-2 format, containing directly repeated hexamers (AGGTCA-like), separated by two bases. Both 
elements directly interacted with HNF-4α and luciferase reporter constructs containing the hOCT1 
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promoter were strongly activated by HNF-4α. Mutagenesis of either DR-2 element severely decreased 
the HNF-4α-mediated activation of the hOCT1 promoter, indicating that the integrity of both elements is 
functionally important. HNF-4α-supported expression of hOCT1 was efficiently suppressed by bile 
acids. The synthetic FXR ligand GW4064 and the bile acid CDCA were equally effective in reversing 
HNF-4α activation of endogenous hOCT1 mRNA expression in cultured liver cells, indicating that this 
effect depends on the bile acid receptor FXR. Furthermore, the FXR-induced repressor SHP 
counteracted activation of the endogenous and reporter-linked hOCT1 promoters by HNF-4α.  
 
The hOAT2 gene is transactivated by HNF-4α and suppressed by bile acids (Paper 2). We identified 
a near-consensus binding motif for HNF-4α within the hOAT2 promoter. A luciferase-linked hOAT2 
promoter fragment was activated upon cotransfection of an HNF-4α expression vector in hepatic 
cells, whereas mutagenesis of the motif abolished HNF-4α activation. Short interfering RNAs against 
HNF-4α reduced endogenous OAT2 expression, demonstrating the role for HNF-4α in maintaining 
the baseline level of hOAT2 gene. While the genes coding for hOCT1 and hOAT2 are both regulated 
by HNF-4α, the exact modes of regulation differ: there is a single direct repeat-1 (DR-1) element with 
strong binding properties for HNF-4α in the hOAT2 promoter, while activation of the hOCT1 promoter 
by HNF-4α depends on two adjacent lower affinity DR-2 elements. Treatment of cells with either 
CDCA or GW4064 and exogenous expression of bile acid-inducible repressor SHP reversed the 
HNF-4α effect on both the hOAT2 promoter activity and endogenous hOAT2 mRNA expression. Bile 
acid-mediated suppression of hOAT2 and hOCT1 gene expression may coordinately decrease 
hepatocellular uptake of drugs and xenobiotics by the two transporters in the presence of increased 
concentrations of bile acids. We also observed that bile acids and GW4064 decreased HNF-4α 
mRNA and protein levels in liver-derived cells, thus reducing nuclear HNF-4α binding to DNA.  
 
The human NTCP gene is activated by GR and PGC-1α, and suppressed by bile acids via a SHP-
dependent mechanism (Paper 3). We showed that the hNTCP gene is a target for induction by 
glucocorticoids and the glucocorticoid receptor (GR). The hNTCP mRNA expression and the reporter-
linked hNTCP promoter were inducible by GR and its agonist dexamethasone. Antiglucocorticoids 
suppressed GR-activation of hNTCP expression, demonstrating the specificity of the effect. 
Mutagenesis and DNA-binding assays identified a GR response element immediately upstream of the 
transcription start site of the hNTCP gene. Our group had previously shown that the hASBT gene is 
activated by GR and its ligands. Thus, glucocorticoids regulate bile acid uptake in the liver and intestine 
in a coordinated manner. We also discovered that GR-activation of hNTCP expression is enhanced by 
the transcriptional coactivator PGC-1α. Activation of the hASBT gene by GR was not affected by PGC-
1α, indicating that it coactivates GR promoter-specifically. We found that GR-activation of hNTCP 
expression was suppressed by bile acids, in a manner dependent on the bile acid receptor FXR. The 
FXR-induced transcriptional repressor SHP suppressed GR-induction of the hNTCP promoter and of 
hNTCP mRNA expression. In summary, we elucidated a mechanism for bile acid-dependent negative 
feedback of hepatic bile acid uptake in humans. GR-dependent induction of the hASBT gene could also 
be suppressed by SHP, implying that GR is also a target for bile acid-mediated suppression of hASBT. 
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The nuclear receptor for bile acids, FXR, transactivates the human OSTα and OSTβ genes (Paper 4). 
We hypothesized that bile acids regulate the expression of the OSTα/OSTβ genes, encoding the bile 
acid export system in ileal enterocytes. Indeed, we obtained strong evidence that human OSTα/OSTβ 
genes are induced by bile acids through ligand-dependent activation by the bile acid receptor FXR. FXR 
agonists induced endogenous mRNA levels of OSTα and OSTβ in cell lines, an effect abolished by 
small interfering RNAs against FXR. The OST mRNAs were also induced in response to bile acids in 
human ileal biopsies. This novel method of short-term culturing of human biopsies serves as a unique 
ex vivo model to study human intestinal gene expression. Luciferase constructs containing the OSTα or 
OSTβ promoter were activated by FXR in the presence of its ligand. Two functional FXR-binding motifs 
were identified in the OSTα gene, and one in the OSTβ gene. We verified that all three motifs in OST 
promoters bound the FXR-RXRα heterodimer. Targeted mutation of the FXR response elements 
reduced the inducibility of both OST promoters. By coordinated control of OSTα/OSTβ expression, bile 
acids adjust their own efflux from enterocytes in response to changes in intracellular bile acid levels. 
Our data emphasize the role of FXR as a master regulator of bile acid transport.  
 
Regional distribution of solute carrier mRNA expression along the human intestinal tract (Paper 5). 
Distribution of 15 human solute carrier (SLC) transporter mRNAs in histologically normal biopsies 
from five intestinal regions of 10 patients was studied. Nine SLC mRNAs were detectable: ASBT, 
CNT1/2, ENT2, OATP2B1, OCTN1/2, PEPT1, and SERT. The bile acid uptake system ASBT is an 
attractive target for drugs designed as bile acid-derivatives. CNT1, CNT2, and ENT2 are nucleoside 
transporters, important for anticancer and antiviral therapy with nucleoside analogues. OATP2B1 
transports steroids, pravastatin, and fexofenadine. OCTN1 and OCTN2 are organic cation/carnitine 
transporters, linked to inflammatory bowel disease. PEPT1 mediates the uptake of nutrient-derived 
peptides and peptidomimetic drugs. Serotonin transporter (SERT) functions as a terminator of 
serotonin signalling. We observed three expression patterns: 1) SLCs predominant in the small 
intestine (CNT1, CNT2, ASBT, SERT, PEPT1) 2) SLCs expressed in all intestinal sections at similar 
levels (OCTN1, OATP2B1) 3) SLCs expressed at higher levels in colon (OCTN2, ENT2). We 
observed high individual variability in SLC expression, resulting from genetic, hormonal, and dietary 
variation or from different exposure to drugs. Our screening approach may provide physiological 
support for regulatory studies of these genes: Consistent with the human ASBT gene being activated 
by GR, ileal ASBT mRNA expression was elevated in a patient receiving glucocorticoids.  
 
Value of the presented work 
Studying the mechanisms that mediate alterations in transporter gene expression has yielded insights 
into factors that affect the efficiency of transmembrane transport in the human liver and intestine, and 
may provide us with new tools to modulate drug absorption and elimination. Additionally, this work may 
advance our understanding of the enterohepatic pathologies, and suggest novel targets for therapy. 
Quantitative knowledge of transporter expression levels in the healthy intestine may assist in defining 
pathological changes in transporter expression.  
